Keros Therapeutics KROS Cash Flow Statement (2019-2026)

NASDAQ KROS
$11.10 -0.21 (-1.85%)
As of: Sep 10, 2026 · 1:27 PM EDT
Reported Financials

Keros Therapeutics Quarterly Cash Flow Statement

Periods 29 quarters
Latest Jun 2026

Keros Therapeutics cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 29 quarters of results from Mar 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Operating Activities
Net Income
-15.62M-20.30M-6.94M-24.19M-27.27M-23.51M-29.72M-38.87M-41.34M-43.28M-46.45M-43.11M-45.26M-52.96M-46.03M148.45M-30.70M-7.28M-23.46M-28.71M
Share-based CompensationStock Comp.
2.85M3.08M3.29M4.39M4.79M4.75M4.75M5.69M7.04M8.71M7.32M8.07M8.79M8.82M9.20M8.86M8.54M3.99M7.30M
Cash from OperationsCash from Ops.
-17.64M-14.44M-19.57M-1.43M-22.59M-24.60M-21.44M-34.23M-30.83M-33.98M-25.46M-44.56M-39.80M-30.50M-46.01M161.17M-29.62M3.25M-27.29M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.10M0.12M0.20M0.20M0.21M0.21M0.32M0.52M0.35M0.34M0.34M0.34M0.35M0.56M0.57M0.58M0.59M0.61M0.62M
Change in Working Capital
Change in ReceivablesChange Receivables
0.10M-0.10M18.00M-18.00M0.14M0.08M-0.22M0.38M2.35M14.55M-1.48M-12.32M0.07M
Change in Account PayablesChange Payables
-1.64M1.44M0.82M-0.67M4.66M-4.99M0.59M1.32M-0.57M-0.18M1.04M0.02M1.61M-1.59M-0.29M2.02M-1.37M-2.96M-0.70M
Change in Accured ExpensesChange Accured Exp.
0.20M1.65M-0.10M0.36M-0.58M1.28M4.26M-1.98M1.17M0.27M5.79M-5.35M0.90M8.71M-1.30M-3.58M2.67M-4.79M-4.43M
Change in TaxesChange Taxes
10.04M-3.72M-2.17M
Other Working Capital ChangesOther WC Changes
3.31M-2.38M-0.77M
Investing Activities
Capital ExpendituresCapex
0.51M0.14M0.16M0.15M0.57M0.18M0.35M1.06M0.31M0.55M0.54M0.95M0.31M0.39M0.29M0.56M0.72M0.13M0.13M
Cash from Investing ActivitiesCash from Investing
-0.51M-0.14M-0.16M-0.15M-0.57M-0.18M-0.35M-1.06M-0.31M-0.55M-0.54M-0.95M-0.31M-0.39M-0.29M-0.56M-0.72M-0.13M-0.13M
Financing Activities
Other financing activitiesOther financing
0.06M0.04M0.24M0.12M0.50M0.10M0.10M0.37M1.74M0.31M0.80M5.72M2.97M1.01M2.44M0.00M0.02M0.12M0.01M
Cash from Financing ActivitiesCash from Financing
0.06M0.04M28.42M0.12M10.19M48.58M61.42M107.68M1.74M0.28M69.25M156.80M3.53M155.94M75.54M0.00M0.02M0.14M-378.63M
Change in Capital Stock
Net Equity Issued and RepurchasedNet Equity Issued
9.69M48.49M61.40M107.31M68.52M151.34M4.36M73.10M151.10M-151.10M
Additional items
Change in Cash
-18.09M-14.55M8.69M-1.46M-12.96M23.80M39.62M72.38M-29.40M-34.25M43.25M111.30M-36.58M125.06M29.25M160.61M-30.33M3.26M-406.06M
Free Cash FlowFCF
-18.15M-14.59M-19.72M-1.57M-23.16M-24.78M-21.79M-35.30M-31.14M-34.53M-26.00M-45.51M-40.11M-30.89M-46.30M160.61M-30.34M3.12M-27.43M
Net Cash FlowNCF
-18.09M-14.55M8.69M-1.46M-12.96M23.80M39.62M72.38M-29.40M-34.25M43.25M111.30M-36.58M125.06M29.25M160.61M-30.33M3.26M-406.06M